Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03274804 | Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC(PICCASSO) | completed | Phase 1 | 20 | University Hospital HeidelbergOTHER | 1 | Jun 7, 2022 |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT02833753 | Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI | completed | Phase 1 | 14 | University of Massachusetts, WorcesterOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT02935309 | Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT03391232 | PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)(OBERTO) | completed | Phase 1 / Phase 2 | 11 | Treos Bio ZrtINDUSTRY | 2 | May 26, 2022 | clinicaltrials |
| NCT00416351 | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT01113736 | Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy(AlloMem) | completed | Phase 1 | 10 | University Hospitals Cleveland Medical CenterOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | completed | Phase 1 | 18 | Stony Brook UniversityOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01154335 | Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 | 18 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03974594 | Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients | completed | Phase 1 | 64 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02641873 | A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 4 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02249650 | To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.(TSB-9-W1) | completed | Phase 1 | 21 | Taiwan Sunpan Biotechnology Development Co., Ltd.OTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | completed | Phase 1 | 283 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 29, 2022 | clinicaltrials |
| NCT03254394 | Lidocaine for Oxaliplatin-induced Neuropathy | completed | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | completed | Phase 1 / Phase 2 | 53 | Green Cross CorporationINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03985072 | Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor | completed | Phase 1 | 67 | Andes BiotechnologiesINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02248805 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | completed | Phase 1 | 95 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02636036 | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors(SPICE) | completed | Phase 1 | 51 | Akamis BioINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05110118 | Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects | completed | Phase 1 | 112 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Nov 5, 2021 | clinicaltrials |
| NCT02777710 | Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers(MEDIPLEX) | completed | Phase 1 | 48 | Centre Leon BerardOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03564912 | Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC | completed | Phase 1 / Phase 2 | 160 | Zhejiang UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01270698 | Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer | completed | Phase 1 | 26 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04607291 | Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening | completed | Phase 1 | 183 | Roswell Park Cancer InstituteOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT00844233 | Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer(PARAGON-II) | completed | Phase 1 / Phase 2 | 40 | Boston Scientific CorporationINDUSTRY | 3 | Jul 21, 2021 | clinicaltrials |
| NCT02270606 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | completed | Phase 1 | 14 | Virginia Commonwealth UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT02510001 | MEK and MET Inhibition in Colorectal Cancer(MErCuRIC1) | completed | Phase 1 | 82 | University of OxfordOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT00695201 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer | completed | Phase 1 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT03300570 | Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2021 | clinicaltrials |
| NCT01075048 | ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 131 | Daiichi SankyoINDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01966289 | SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | completed | Phase 1 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02953782 | Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 78 | Gilead SciencesINDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01801930 | A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer | completed | Phase 1 | 24 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03542214 | Calcium Electroporation for the Treatment of Colorectal Cancer | completed | Phase 1 | 6 | Zealand University HospitalOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01927341 | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | completed | Phase 1 / Phase 2 | 53 | PfizerINDUSTRY | 7 | Feb 18, 2021 | clinicaltrials |
| NCT02008383 | Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer(CaboMAb) | completed | Phase 1 | 29 | John Strickler, M.D.OTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT01781403 | Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer | completed | Phase 1 | 22 | Asan Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT01407107 | Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer | completed | Phase 1 | 13 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT03081494 | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 11, 2020 | clinicaltrials |
| NCT00969046 | Dose-Escalation Study in Advanced Colon Cancer Patients | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2022source: clinicaltrials